Wuhan spring bioengineering co., ltd.

The company has established the development idea of high starting point and high standard, established the quality consciousness of 65,438+0,000% high quality, invested 25000m2 workshop according to GMP standard, introduced advanced equipment such as FUTURA automatic capsule filling machine of Italian GM2 company and UPS300 blister packaging machine of German ullman company, and has the production capacity of hard capsules, tablets, pills and granules. In 2003, the company built a national first-class factory covering an area of 97 mu.

The company has established marketing workstations in more than 20 provinces, 100 cities and 1200 county-level regions, forming a huge marketing network.

Hubei Chuntian Pharmacy Chain Co., Ltd., a subsidiary of Chuntian Bio, is establishing 65,438+0,000 Chuntian Pharmacy chain stores nationwide, and has built a domestic first-class drug distribution center in Wuhan, covering an area of 5,620 square meters, which can meet the distribution needs of 200 pharmaceutical chain stores at the same time. At the same time, it is planned to establish the largest pharmaceutical trading center in China covering an area of 360 mu in three years at the intersection of Beijing-Zhuhai and Shanghai-Chengdu Expressway.

The company is committed to bioengineering and research and development of new medicines. There are two scientific research institutions: First, the Spring Bioengineering Research Center of Wuhan University, headed by Professor Tian Bo, an academician of China Academy of Sciences, a famous virology bioengineering expert at home and abroad and a doctoral supervisor, is using genetic engineering to develop new anti-tumor and anti-AIDS drugs. The second is the company's scientific research center, which is the technical center of provincial high-tech enterprises. Mainly engaged in research and development, cooperative research and development and the introduction and development of related products and technologies. At the same time, the Center actively cooperates with Wuhan University, Fudan University, Wuhan Institute of Virology, Chinese Academy of Sciences and other universities and research institutes, and has established a collaborative laboratory with spring characteristics to provide stable and lasting high-tech products for the company. The company's gene engineering eukaryotic expression technology and slow-release pharmaceutical technology are leading in China. The company has 55 technicians, and the annual investment in scientific research accounts for nearly 5% of the total income. There are 8 new biological drugs of Class I and II under development, and more than 3 and 4 new drugs 10.